Abstract
Despite the preferable properties of well-defined cationic peptides for small interfering RNA (siRNA) delivery, their application as siRNA carriers remains limited due to their poor binding affinity with short-chain RNAs. In this study, we investigated the feasibility of a novel strategy for circumventing this limitation, by assessing the utility of multimeric conjugates of siRNA for improving the binding affinity of siRNAs with cationic peptides and the extent of intracellular delivery. Protamine, a natural and arginine-rich peptide, was used to produce stably condensed polyelectrolyte complexes (PECs) with multimeric siRNAs (multi-siRNA) with a size of 120 nm while conventional siRNA/protamine particles are over 500 nm. The formulated multi-siRNA/protamine PECs showed greatly enhanced stability, intracellular uptake, and biocompatibility compared to conventional, monomeric (mono)-siRNA/protamine particles. With the addition of chloroquine, multi-siRNA/protamine PECs successfully inhibited target gene expression in MDA-MB-435 cells, a breast cancer cell line, even in the presence of serum protein. This study demonstrates that multi-siRNA conjugates greatly facilitate the formulation of nano-sized protamine-based carriers and significantly improve intracellular delivery in vitro compared to common siRNAs, and therefore may provide a platform for the design of peptide-based siRNA delivery systems for in vivo applications.
Similar content being viewed by others
References
Brewer, L.R., M. Corzett, and R. Balhorn. 1999. Protamine-induced condensation and decondensation of the same DNA molecule. Science 286: 120–123.
Choi, Y.S., et al. 2010. The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine. Biomaterials 31: 1429–1443.
Decuzzi, P., et al. 2009. Intravascular delivery of particulate systems: does geometry really matter? Pharmaceutical Research 26: 235–243.
Fischer, D., et al. 2004. Poly(diallyldimethylammonium chlorides) and their N-methyl-N-vinylacetamide copolymer-based DNA-polyplexes: role of molecular weight and charge density in complex formation, stability, and in vitro activity. International Journal of Pharmaceutics 280: 253–269.
Fischer, D., et al. 2003. In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials 24: 1121–1131.
Heuer, D.M., S. Saha, and L.A. Archer. 2003. Topological effects on the electrophoretic mobility of rigid rodlike DNA in polyacrylamide gels. Biopolymers 70: 471–481.
Huang, Y., et al. 2013. Curb challenges of the “Trojan Horse” approach: smart strategies in achieving effective yet safe cell-penetrating peptide-based drug delivery. Advanced drug delivery reviews 65: 1299–1315.
Kim, W.J., and S.W. Kim. 2009. Efficient siRNA delivery with non-viral polymeric vehicles. Pharmaceutical Research 26: 657–666.
Kiselev, A., et al. 2013. Characterization of reducible peptide oligomers as carriers for gene delivery. International Journal of Pharmaceutics 441: 736–747.
Kumar, P., et al. 2008. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 134: 577–586.
Kundu, A.K., et al. 2012. Stability of lyophilized siRNA nanosome formulations. International Journal of Pharmaceutics 423: 525–534.
Lee, S.H., et al. 2012. Small-interfering RNA (siRNA)-based functional micro- and nanostructures for efficient and selective gene silencing. Accounts of Chemical Research 45: 1014–1025.
Makris, M., R.E. Hough, and S. Kitchen. 2000. Poor reversal of low molecular weight heparin by protamine. British Journal of Haematology 108: 884–885.
Meade, B.R., and S.F. Dowdy. 2007. Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Advanced Drug Delivery Reviews 59: 134–140.
Mok, H., et al. 2010. Multimeric small interfering ribonucleic acid for highly efficient sequence-specific gene silencing. Nature Materials 9: 272–278.
Mok, H., and T.G. Park. 2008. Self-crosslinked and reducible fusogenic peptides for intracellular delivery of siRNA. Biopolymers 89: 881–888.
Nguyen, J., and F.C. Szoka. 2012. Nucleic acid delivery: the missing pieces of the puzzle? Accounts of Chemical Research 45: 1153–1162.
Pernodet, N., M. Maaloum, and B. Tinland. 1997. Pore size of agarose gels by atomic force microscopy. Electrophoresis 18: 55–58.
Reynolds, F., R. Weissleder, and L. Josephson. 2005. Protamine as an efficient membrane-translocating peptide. Bioconjugate Chemistry 16: 1240–1245.
Scholz, C., and E. Wagner. 2012. Therapeutic plasmid DNA versus siRNA delivery: common and different tasks for synthetic carriers. Journal of Controlled Release 161: 554–565.
Tseng, Y.C., S. Mozumdar, and L. Huang. 2009. Lipid-based systemic delivery of siRNA. Advanced Drug Delivery Reviews 61: 721–731.
Won, Y.W., et al. 2011. Poly(oligo-d-arginine) With Internal Disulfide Linkages as a Cytoplasm-sensitive Carrier for siRNA Delivery. Molecular Therapy 19: 372–380.
Wyman, T.B., et al. 1997. Design, synthesis, and characterization of a cationic peptide that binds to nucleic acids and permeabilizes bilayers. Biochemistry 36: 3008–3017.
Yewale, C., et al. 2013. Proteins: emerging carrier for delivery of cancer therapeutics. Expert Opinion on Drug Delivery 10: 1429–1448.
Acknowledgments
This study was supported by a grant from the National R&D Program for Cancer Control, Ministry for Health and Welfare, Republic of Korea (1220050).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yoo, H., Mok, H. Evaluation of multimeric siRNA conjugates for efficient protamine-based delivery into breast cancer cells. Arch. Pharm. Res. 38, 129–136 (2015). https://doi.org/10.1007/s12272-014-0359-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-014-0359-8